Merck acquires flu specialist Cidara Therapeutics for USD 9.2 billion
Cidara Therapeutics, a portfolio company of Arctic Aurora LifeScience, has agreed to be acquired by the large pharmaceutical company Merck for $9.2 billion. This represents a 109% premium over Cidara’s last closing stock price.
Cidara’s lead drug candidate, CD388, is currently undergoing phase 3 trials for the prevention of influenza infections in individuals at a higher risk of disease complications. Flu is a well-known disease that affects many people every year. The primary strategy for preventing it is to get a flu shot before the start of each flu season. However, as the flu virus is highly susceptible to mutation, vaccine manufacturers must adapt their products every year. Additionally, current vaccines are only 40–60% effective in the general population and provide weaker protection for high-risk groups and the elderly.
In contrast, CD388 is an antiviral drug that targets a conserved part of the virus, so it does not need to be changed every year. It is connected to an antibody fragment with modifications that ensure a longer half-life and a potentially more durable effect that lasts for the whole flu season. The company is currently targeting high-risk patients and the elderly, achieving up to 76% protection in phase 2 trials earlier this year.
This acquisition would be a good strategic fit for Merck, given their existing strong presence in infectious diseases, particularly HIV and RSV. Furthermore, the patent for their primary cancer drug, Keytruda, is due to expire at the end of 2028. As Keytruda generates approximately USD 30 billion in revenues — almost half of Merck’s total sales — the company is actively working to replenish its commercial and development pipeline before Keytruda revenues start to decline. The acquisition of Cidara therefore fits well into this strategy.
Latest news
Arctic Asset Management - Obesity companies strike deal with the Trump administration increasing visibility for the accelerating obesity market
Novo Nordisk and Eli Lilly are set to lower the prices of their obesity medicines. As a result of the price agreement, they will gain access to a larger patient population in the US, which is expected to offset the price reductions.
Arctic Asset Management - Markedskommentar oktober 2025
Nyhetsbildet i oktober ble i stor grad preget av handelskrigen mellom USA og Kina. I begynnelsen av måneden innførte Kina økt kontroll på eksport av sjeldne jordarter og kritiske mineraler. Som respons truet Trump med kraftige mottiltak, inkludert 100 % tariff på kinesiske varer fra 1. november. Markedene reagerte kraftig både den ene og andre veien ettersom utspillene endret seg. Mot slutten av måneden møttes Trump og XI til forhandlinger og det ble i etterkant annonsert en ettårig pause i forhandlingene. Forhandlingene har imidlertid fortsatt i etterkant og underliggende strukturelle uenigheter vedvarer.
Arctic Asset Management - Arctic Midt i Måneden - Halv pris, fantastisk avkastning og solide utbytter – børsoptimismen lever i Norden
Obligasjonsmarkedet har opplevd historisk stort volum og det norske aksjemarkedet har levert like god vekst som det amerikanske, men handles til halv pris (P/E). Samtidig byr Norden på sterke selskaper, solide dividender og gode muligheter for meravkastning gjennom håndplukkede porteføljer. I denne episoden av Arctic Midt i Måneden diskuterer vi hva som driver optimismen i markedet – fra rentebaner til resultatsesong. Bak mikrofonene sitter Albert Collett sammen med forvalterne Cathrine Foyn og Sindre Sørbye.
Arctic Asset Management - RNA therapy specialists Avidity Biosciences to be acquired by Novartis for USD 12 billion
On 26 October, Avidity Biosciences, a portfolio company of Arctic Aurora LifeScience, announced an agreement to be acquired by Novartis at a 46% premium to the previous close of the stock, or nearly 90% above the market value when rumours of the acquisition first emerged.
Arctic Asset Management - Markedskommentar september 2025
September ble en stabil børsmåned. Norden og Oslo var nær uendret med -0,1 % avkastning for både fondsindeksen OSEFX og den nordiske VINX Benchmark Cap målt i NOK. Så langt i år er Oslo Børs opp med 17,4 %. I USA steg S&P 500 indeksen med 3,6 % i september målt i dollar, og den europeiske STOXX 600 indeksen steg med 1,5 % målt i euro. Verdensindeksen (MSCI World NR) steg 2,4 % i september og er opp 2,9 % i norske kroner hittil i år.
Arctic Asset Management - Oncology company Merus to be acquired by Genmab for a 41% premium
Danish biotech Genmab to pay USD 8 billion to add Merus’ bispecific antibodies to their platform